A detailed history of Clearwater Capital Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Clearwater Capital Advisors, LLC holds 1,738 shares of ABBV stock, worth $290,680. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,738
Previous 1,947 10.73%
Holding current value
$290,680
Previous $301,000 4.98%
% of portfolio
0.04%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$159.82 - $182.1 $33,402 - $38,058
-209 Reduced 10.73%
1,738 $316,000
Q4 2023

Feb 06, 2024

BUY
$137.6 - $154.97 $12,108 - $13,637
88 Added 4.73%
1,947 $301,000
Q3 2023

Oct 24, 2023

BUY
$133.59 - $154.65 $9,217 - $10,670
69 Added 3.85%
1,859 $277,000
Q2 2023

Aug 08, 2023

BUY
$132.51 - $164.9 $5,432 - $6,760
41 Added 2.34%
1,790 $241,000
Q1 2023

May 10, 2023

SELL
$144.61 - $166.54 $5,639 - $6,495
-39 Reduced 2.18%
1,749 $278,000
Q2 2022

Jul 21, 2022

BUY
$137.62 - $174.96 $5,367 - $6,823
39 Added 2.23%
1,788 $274,000
Q1 2022

May 03, 2022

BUY
$131.98 - $163.75 $230,833 - $286,398
1,749 New
1,749 $284,000
Q1 2019

May 13, 2019

SELL
$77.14 - $90.79 $201,103 - $236,689
-2,607 Closed
0 $0
Q4 2018

Jan 22, 2019

BUY
$77.85 - $96.01 $29,582 - $36,483
380 Added 17.06%
2,607 $240,000
Q3 2018

Oct 17, 2018

BUY
$88.91 - $98.84 $198,002 - $220,116
2,227 New
2,227 $211,000
Q2 2018

Aug 16, 2018

SELL
$89.78 - $106.23 $184,497 - $218,302
-2,055 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$92.01 - $123.21 $189,080 - $253,196
2,055 New
2,055 $195,000
Q4 2017

Feb 05, 2018

SELL
$89.56 - $98.21 $259,276 - $284,317
-2,895 Closed
0 $0
Q3 2017

Oct 19, 2017

BUY
$69.85 - $89.22 $202,215 - $258,291
2,895
2,895 $263,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $296B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Clearwater Capital Advisors, LLC Portfolio

Follow Clearwater Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearwater Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearwater Capital Advisors, LLC with notifications on news.